Lance Liotta
Overview
Explore the profile of Lance Liotta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
1917
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Almosuli M, Kirtava A, Chkhotua A, Tsveniashvili L, Chanishvili N, Irfan S, et al.
Commun Biol
. 2025 Feb;
8(1):175.
PMID: 39905205
Despite much promise in overcoming drug-resistant infections, clinical studies of bacteriophage antibacterial therapy have failed to show durable effectiveness. Although lysogeny plays an important role in bacterial physiology, its significance...
2.
Slattery 3rd W, Andalibi A, Angeli S, Babu S, Bolt K, Britt W, et al.
Otol Neurotol
. 2024 Oct;
45(10):e670-e678.
PMID: 39473327
No abstract available.
3.
Cornero R, Irfan S, Cachaco S, Zhou W, Byne A, Howard M, et al.
Methods Mol Biol
. 2024 Jan;
2742:105-122.
PMID: 38165619
The combination of advanced mass spectrometry and enrichment-based sample preparation methods has enhanced analytical capabilities in clinical proteomics. In this chapter, we describe a method of proteome analysis to identify...
4.
Carter R, Alanazi F, Sharp A, Roman J, Luchini A, Liotta L, et al.
J Biol Chem
. 2023 Oct;
299(12):105353.
PMID: 37858677
The PD-1/PD-L1 checkpoint pathway is important for regulating immune responses and can be targeted by immunomodulatory drugs to treat a variety of immune disorders. However, the precise protein-protein interactions required...
5.
Andalibi A, Veneziano R, Paige M, Buschmann M, Haymond A, Espina V, et al.
SLAS Discov
. 2023 Mar;
28(6):270-274.
PMID: 36921802
With over 39,000 students, and research expenditures in excess of $200 million, George Mason University (GMU) is the largest R1 (Carnegie Classification of very high research activity) university in Virginia....
6.
Abu-Khalaf M, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, et al.
NPJ Precis Oncol
. 2023 Feb;
7(1):18.
PMID: 36797347
Endocrine therapy (ET) in combination with CDK4/6 inhibition is routinely used as first-line treatment for HR+/HER2- metastatic breast cancer (MBC) patients. However, 30-40% of patients quickly develop disease progression. In...
7.
Jeiran K, Gordon S, Sviridov D, Aponte A, Haymond A, Piszczek G, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232786
ApoB-100 is a member of a large lipid transfer protein superfamily and is one of the main apolipoproteins found on low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) particles. Despite...
8.
Eke I, Aryankalayil M, Bylicky M, Makinde A, Liotta L, Calvert V, et al.
Sci Rep
. 2022 Mar;
12(1):3500.
PMID: 35241721
The efficacy of molecular targeted therapy depends on expression and enzymatic activity of the target molecules. As radiotherapy modulates gene expression and protein phosphorylation dependent on dose and fractionation, we...
9.
Hetrick B, Chilin L, He S, Dabbagh D, Alem F, Narayanan A, et al.
Cell Rep Methods
. 2022 Mar;
2(3):100181.
PMID: 35229082
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S)-pseudotyped viruses are commonly used for quantifying antiviral drugs and neutralizing antibodies. Here, we describe the development of a hybrid alphavirus-SARS-CoV-2...
10.
Holmes F, Levin M, Cao Y, Balasubramanian S, Ross J, Krekow L, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-26.
PMID: 35100698
Purpose: To identify proteomic and genomic alterations in residual disease (RD) for human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) after preoperative trastuzumab (H), lapatinib (L), or...